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Abstract 
Background: In resource-poor settings, treatment adherence is a major determinant of response to anti-malarial 
drugs as most are taken at home without medical supervision. Evidence on adherence to artemisinin-based combi-
nation therapy (ACT) is limited. The study aimed to measure adherence and identify reasons for non-adherence to a 
3-day, fixed-dose combination (FDC) of artesunate–amodiaquine (ASAQ), the first-line treatment for uncomplicated 
malaria in the Médecins Sans Frontières project in the Shabunda Health Zone, South Kivu, Democratic Republic of 
Congo, a highly malarious and conflict-affected area.
Methods: The study took place in the health centres/outpatient departments of the Shabunda general hospital, the 
quarter Mbangayo, and participant households. Patients prescribed FDC ASAQ were visited at home on the day after 
their regimen finished and asked to complete an adherence questionnaire. Patients/caretakers were also interviewed 
when exiting the outpatient department to understand their attitude towards FDC ASAQ and assess the quality of the 
prescribing process.
Results: 148 patients/caretakers completed the adherence questionnaire: 11.5 % (17/148, 95 % CI 7–17) had ≥1 tab-
let left at the time of the home visit and were defined as certainly non-adherent; 13.5 % (20/148, 95 % CI 8–19) were 
probably non-adherent; thus total non-adherence was 25.0 % (37/148, 95 % CI 18–32). 75 % (111/148, 95 % CI 68–82) 
were defined as probably adherent. In exit interviews, 87.5 % (105/120) knew they had malaria or could name the cor-
rect signs/symptoms. 89 % (107/120) could identify FDC ASAQ as anti-malarials among all tablets given and correctly 
repeat the intake instructions given at the outpatient department.
Conclusions: This is the first study to assess adherence to an FDC of ACT under real treatment conditions in a 
context of high instability. High quality prescribing of anti-malarials at health centre level and patient adherence to 
the correct intake of ACT were possible in this setting. Adherence to treatment regimen requires careful and constant 
monitoring which might be better guaranteed at health centre rather than community level. It could, nevertheless, 
be a precondition to the successful introduction of home- or community based management of malaria.
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Background
Malaria, despite being treatable, remains a major killer in 
many low-income countries, with around half the world’s 
population at risk from the disease. Approximately 
627,000 deaths occur every year, 90  % in sub-Saharan 
Africa and 85  % in children under 5  years of age [1, 2]. 
In addition to preventive measures, prompt and accurate 
diagnosis (through microscopy or rapid-diagnostic test-
ing) followed by treatment with an artemisinin-based 
Page 2 of 11Gerstl et al. Malar J  (2015) 14:414 
combination therapy (ACT) is the current main malaria 
control strategy. ACT has been adopted as national pol-
icy for first-line treatment in 79 of the 88 countries where 
Plasmodium falciparum is endemic [2]. ACT, however, 
should not be considered the definitive solution to the 
problem of anti-malarial resistance and correct and effec-
tive treatment of malaria presents enormous challenges, 
especially in sub-Saharan Africa [3]. Incorrect treatment 
intake and inadequate drug dosing increases drug pres-
sure and thus the risk of developing resistance [4]. Wor-
ryingly, there are already concerns that ACT efficacy has 
declined in some parts of Asia [5, 6].
The correct use of a treatment involves correct diag-
nosis, prescription, dosage, and adherence. Factors that 
influence patient adherence include frequency of dos-
ing, number of pills, duration of treatment, side-effects, 
cost of treatment, household income, concomitant treat-
ment intake, education level, sufficient explanation of 
the importance of full-course adherence by the treat-
ment prescriber, attitudes towards the sharing and sav-
ing of medications, and caregivers’ perception of the 
severity of the illness [7–14]. Only some of these factors 
can be directly influenced by treatment providers, such 
as ensuring complete and clear explanations on how to 
take the treatment and limiting the number of treatment 
schedules per patient.
Adherence to treatment is a major determinant of the 
response to anti-malarial drugs, especially for remote 
and unstable settings where home-based or commu-
nity-based programmes for managing malaria might be 
one of the few strategies able to overcome barriers to 
accessing health care [15, 16]. Adherence should be reg-
ularly assessed in order to ensure that treatment strate-
gies remain effective and to give the best chance of a 
positive treatment outcome. Such evaluations should be 
used as practical tools, allowing for appropriate action 
to improve patient adherence if indicated. However, the 
evidence on adherence to ACT is limited [17] and there 
is no consensual standard for what constitutes adequate 
adherence [18].
Fixed-dose combinations (FDC) might improve adher-
ence compared with co-blistered drugs [19–21]. With the 
artesunate–amodiaquine fixed-dose combination (FDC 
ASAQ), adults take just two tablets per day compared 
with eight in the co-blister formulation [22]. Moreover, 
patients cannot separate the two drugs, thus avoiding 
monotherapy and preventing the development of drug 
resistance. Only two studies have evaluated FDC ASAQ, 
with reported adherences of 83  % in Madagascar and 
90  % in Benin; however, in both studies, patients were 
expecting a home visit at the end of the treatment course, 
which might have led to improved treatment intake [23, 
24]. In a study carried out by Médecins Sans Frontières 
(MSF) in 2009 in Boguila, Central African Republic, 
adherence to an FDC of ACT (Coartem™) was just 60.8 % 
[25].
In accordance with the national protocol of the Pro-
gramme Nationale de Lutte contre le Paludisme (National 
Malaria Programme) of the Democratic Republic of the 
Congo (DRC), FDC ASAQ is the first-line malaria treat-
ment used in the MSF project in the Shabunda Health 
Zone, South Kivu, DRC. All malaria cases are confirmed 
with a rapid diagnostic test (RDT HRP2 SD Bioline®) 
or microscopy at hospital level when indicated. Malaria 
is holoendemic (perennial and intense transmission) 
in Shabunda Health Zone, with the highest number of 
cases occurring between September and December. In 
January–October 2013, malaria cases in MSF-supported 
health facilities in Shabunda Health Zone accounted for 
31.4  % of consultations in the outpatient department 
(OPD) (31,630/100,579); 48.4  % (15,313 cases) were in 
children aged under 5 years. Uncomplicated malaria was 
the principal cause of morbidity and the main cause for 
admission to a reference hospital (36.4  %, 3487/9586) 
(MSF, internal source, IPD-OPD database, 2013).
No adherence study has previously been carried out 
in the MSF project in the Shabunda Health Zone. In this 
study, the aim was to measure adherence to the currently 
used FDC ASAQ given over 3  days to treat uncompli-
cated malaria in a highly malarious and conflict-affected 
region and to identify the reasons for non-adherence.
Methods
Study area, period and population
Shabunda town, population approximately 25,000, is the 
capital of Shabunda Health Zone, a region comprising 
20 health areas (“aires de santé”) with a catchment area 
of 172,854 habitants, located in the South Kivu Province 
of DRC, bordering with Rwanda and Burundi to the east 
(Bureau Central Zone Santé de Shabunda, personal infor-
mation, 2013). The area has long been affected by con-
flict. MSF supports a general hospital run by the Ministry 
of Health in Shabunda town, a hospital centre in the vil-
lage of Matili (around 30  km south of Shabunda) both 
providing secondary-level health care, and seven health 
centres (OPDs) providing primary-level health care to 
the whole catchment area.
The study took place in 2013, in the OPD of the gen-
eral hospital of Shabunda and the OPD Mbangayo (also 
situated in Shabunda town) and in the households of the 
study population. Malaria activities are completely inte-
grated in the hospitals and OPD activities. The study was 
conducted during November to coincide with the high-
est period of malaria incidence and therefore to reflect 
the level of adherence when the duration and quality of 
malaria care might vary because of the high caseload.
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Participants
Patient inclusion criteria were: age ≥1 year; a confirmed 
diagnosis via RDT (SD Bioline HRP2®) of uncomplicated 
falciparum malaria, with or without additional diagnoses; 
receipt of a course of FDC ASAQ during normal consul-
tation hours in the MSF-supported OPDs; no previous 
participation of a household member in the study; and 
signed informed consent (adherence study) or verbal 
consent (exit interview). Patients were excluded from the 
adherence study if they were resident ≥30 min from the 
OPDs by foot or lived in Kitete, a “quartier” (quarter) of 
Shabunda town considered inaccessible due to security 
constraints. Kitete borders the river Ulindi, and rebel 
forces have their base on the other bank. Moreover, the 
airstrip, which was under fire 3  days before the start of 
the study, must be crossed to reach Kitete.
Study procedure and data collection
All interviews were held either in one of the local lan-
guages (Swahili or Kirega) or in French. The study was 
supervised by the principal investigator and a field study 
supervisor who was fluent in all spoken languages. Prior 
to initiating the study, 2-days of training were given to 
all interviewers and data collectors. Extra attention was 
paid by the supervisors to discuss and agree on the same 
wording for all interviewers and data collectors while car-
rying out the interviews in the different local languages. 
With the help of role plays, all interviewers and data col-
lectors had sufficient time to familiarize themselves with 
the questionnaires.
Screening
The usual procedures of consultation, treatment pre-
scription and dispensing in the MSF-supported OPDs 
were followed: patients received a health card and a 
malaria RDT if they were suspected of having malaria, 
defined as fever or history of fever in the previous 48 h; 
were prescribed FDC ASAQ in the case of a positive RDT 
and further drugs if necessary; took the first dose of FDC 
ASAQ under supervision at the pharmacy; and were 
given the second and third daily doses to take at home 
with intake instructions.
Before leaving the OPD, a short screening question-
naire was administered by three data collectors: a full 
description of all drugs prescribed was copied from each 
patient’s health card and their address recorded to enable 
subsequent location of their household. All patients, irre-
spective of diagnosis, received the screening question-
naire to avoid raising suspicion among health staff and 
patients/caretakers of patients about the specific purpose 
of the study. Health staff were informed that a study was 
taking place, but the exact purpose of the study was not 
revealed to avoid influencing routine prescribing habits.
Adherence study
Patients prescribed FDC ASAQ were visited at home on 
the day after the last dose should have been consumed. 
If the visit could not be completed, the interviewer tried 
again the following day. No interviews were carried out 
at a later date. Patients needed to be at home to answer 
the questionnaire themselves. For children or patients 
not able to take FDC ASAQ on their own, the caretak-
ers who gave them their treatment had to be present to 
answer the adherence questionnaire. Patients or caretak-
ers who were not able to be located were classified as lost 
to follow-up and excluded from the study.
The semi-structured adherence questionnaire was 
developed in French. It included initial general questions 
about the patient and household: sex, age, education 
level of patient or caretaker, household composition, and 
occupation of head of household. A systematic account 
of how the tablets had been taken was recorded. Patients 
or caretakers were also asked to show the original co-for-
mulated blister package of the FDC ASAQ; if it was still 
available any remaining tablets were counted. Finally, two 
questions on general malaria knowledge were asked. Five 
interviewers administered the adherence questionnaires 
at the home of the patients.
Exit interviews with patients who received FDC ASAQ prior 
to leaving the OPDs
After all the screening questionnaires had been com-
pleted, exit interviews were carried out at the OPDs to 
help understand patient/caretaker attitudes towards FDC 
ASAQ prescription and to assess prescription quality (the 
information and instructions provided to the patient/
caretaker and supervision of the first dose). All patients 
who received FDC ASAQ during normal consultation 
hours were eligible. They or their respective caretakers 
were interviewed upon exiting the OPD consecutively 
until the required number was achieved. Patients/care-
takers were asked to describe how they were planning to 
give/take the FDC ASAQ, followed by a series of system-
atic questions for each treatment dose. Three interview-
ers (who also administered the screening questionnaires) 
conducted the exit interviews at each of the two OPDs.
Definition of adherence
Since there is no standard definition for adherence we 
used definitions shown to be reliable in similar settings 
[25–29]. Patients were classified into three adherence 
categories (Table 1). Certain non-adherence: patients or 
caretakers who showed an FDC ASAQ co-formulated 
blister package still containing any tablets of FDC ASAQ 
at the home visit (certain incomplete intake). Probable 
non-adherence: patients who said that not all the tab-
lets had been taken, but no package could be shown or 
Page 4 of 11Gerstl et al. Malar J  (2015) 14:414 
it was empty (probable incomplete intake); or patients 
who said that not all the tablets had been taken accord-
ing to the prescribed time schedule or dosage, but no 
package could be shown or it was empty (probable incor-
rect intake). Probable adherence: patients with a ver-
bal account of complete treatment exactly following the 
treatment protocol and no package could be shown or it 
was empty (probable correct intake).
Sample size and sampling procedure
On the basis of malaria adherence studies in similar 
areas, adherence was conservatively estimated at 50  % 
[25–28]. With precision of 10  %, α-error of 5  %, and 
loss to follow-up or withdrawal of 20 %, the sample size 
required for the adherence study was 117. An equal num-
ber of patients was included in each OPD. Similar calcu-
lations resulted in a sample size of 117 patients for the 
exit interviews. Again, an equal number of patients was 
included in each OPD. Once the consultations of the day 
were finished in the OPDs, eligible patients were selected 
for the adherence study and assigned a permanent con-
secutive inclusion number. This sampling procedure was 
carried out in the two OPDs until the required number of 
patients/caretakers per OPD was achieved.
Data management and analysis
Data were entered into EpiData 3.0 software (EpiData 
Association, Odense, Denmark). Data were cleaned by 
checking inconsistencies in data entry and responses. 
Data analysis was conducted using SPSS 10.0 for Win-
dows (SPSS Inc., Chicago, USA). Baseline characteris-
tics of patients/caretakers were described (mean age, 
male/female sex ratio, educational level). The pro-
portions of probable/certain (non-) adherence and 
complete/incomplete/correct treatment intake were 
expressed with 95  % confidence intervals (95  % CIs). 
Risk factors for non-adherence such as age, education 
level and knowledge of malaria were analysed. Both p 
value and relative risks (with 95  % CI) were calculated 
where appropriate. The adherence and exit study popu-
lations were compared by comparison of proportions 
using the Chi squared test.
Ethical considerations
The Ethics Review Board of MSF and the Ethics Com-
mittee of DRC granted ethical approval. Authorities at 
all health levels and heads of the different quarters in 
Shabunda town were informed via personal visits before 
the study started. Written consent was sought from 
patients or responsible caretakers of patients before the 
adherence questionnaire was administered. Verbal con-
sent was sought from patients, or responsible caretakers 
participating in the exit interviews.
The adherence and exit questionnaires were anony-
mous. All data remained, throughout data entry and 
analysis, anonymous at the patient level. All participants 
received an explanation of the study purpose in the lan-
guage they were most comfortable with—Swahili, Kirega, 
or French. Participation was voluntary and all partici-
pants were offered the opportunity to refuse participa-
tion at any time without penalty.
Results
Data were collected between November 13 and 21, 2013. 
In total, 856 patients were screened at the two OPDs. Of 
these, 432 received an FDC ASAQ prescription (50.5 %), 
262 (60.6  %) of whom were eligible for inclusion in the 
adherence study; 148 patients/caretakers were finally 
included (Fig.  1). Of the 148 patients in the adherence 
study, 56 (37.8 %) had come without and 92 (37.8 %) with 
a caretaker to the OPDs. General characteristics of the 
adherence study population are shown in Table 2.
Patient adherence
Among the 148 patients interviewed, 11.5  % (17/148, 
95 % CI 7–17) had one or more tablets left at the time of 
the home visit and were defined as certainly non-adher-
ent; 13.5 % (20/148, 95 % CI 8–19) were defined as prob-
ably non-adherent, giving a total of 25.0 % (37/148, 95 % 
CI 18–32) non-adherence. Seventy-five percent (111/148, 
95  % CI 68–82) were defined as probably adherent 
(Table  1). Adherence did not vary significantly between 
the under- and over-5  year age groups, with probable 
adherence of 61.9 % (26/42, 95 % CI 47–76) versus 80.2 % 
(85/106, 95  % CI 72–87), respectively (p  =  0.19). Sev-
enteen (11.5  %, 17/148) of the interviews at home were 
carried out 2  days after the last dose should have been 
consumed. No difference in adherence could be seen 
between the interviews carried out 1 or 2 days after the 
last dose should have been consumed.
Table 1 Classification of  adherence study patients 
by treatment adherence
95 % CI 95 % confidence interval, OPD outpatient department
Classification Inclusions (n = 148)
n % 95 % CI
Certain non-adherence (incomplete) 17 11.5 7–17
Probable non-adherence (probable) 20 13.5 8–19
Incomplete 8 5.4 3–10
Incorrect 12 8.1 4–13
Probable adherence 111 75.0 68–82
1st intake at OPD 74 50.0 42–58
1st intake at home 37 25.0 18–32
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Reasons for incomplete, incorrect or correct intake
The two main reported reasons for incomplete intake 
were sickness after FDC ASAQ intake (28  %, 7/25) and 
no food/sugar available in the household for FDC ASAQ 
intake (20  %, 5/25) (Table  3); 70.6  % (18/25) of patients 
with incomplete intake omitted their last treatment dose. 
The main reason for incorrect intake was immediate 
vomiting after drug intake (66.7 %, 8/12), but otherwise 
malaria treatment had been taken correctly. The main 
reason stated for correct FDC ASAQ treatment intake 
was that the instructions given at the OPD had been fol-
lowed (87.8  %, 65/74) (Table  3). For patients who had 
correctly taken their treatment, but taken the first dose 
at home, 48.6 % (18/37) reported not eating prior to the 
OPD visit (Table 3).
Assessment of possible risk factors and knowledge 
on malaria
None of the risk factors such as age, education level, and 
knowledge of malaria were associated with increased 
risk of non-adherence (n =  37). When adherence study 
patients or their respective caretakers were asked about 
the cause of malaria, 60.8 % (90/148, 95 % CI 52.8–68.4) 
mentioned mosquito bites and 39.2  % (58/148, 95  % CI 
31.6–47.2) claimed not to know the cause of malaria or 
mentioned a wrong cause. In total, 79.1 % (117/148, 95 % 
CI 72.0–85.0) mentioned that sleeping under an insecti-
cide-treated mosquito net is a way of preventing malaria 
and 20.9 % (31/148, 95 % CI 15.0–28.1) did not know any 
means of prevention or mentioned an incorrect means of 
prevention.
General characteristics of the exit interview group
Exit interviews were carried out with 120 patients. 
The general characteristics of this group are shown in 
Table 4. The socio-demographic and clinical characteris-
tics of this group did not differ from those of the adher-
ence study (mean patient age, proportion of patients 





and FDC ASAQ prescription
N = 432
Patients without malaria diagnosis
N = 424
Eligible for adherence survey
N = 262
Included in adherence study
N = 148
N = 14     <1 year old
N = 69     ≥30 minutes walking
distance from OPD
N = 87     Security reasons
N = 32     Lost to follow-up
N = 22     Other household members already interviewed
N = 2       Not present at home for 2 consecutive days
N = 1       Incomplete data
N = 55     Required number
of questionnaires already achieved
N = 2       Refusal to sign written consent form
due to fear of abuse of his/her signature
Fig. 1 Study profile for FDC ASAQ adherence study Shabunda Health Zone, Democratic Republic of the Congo. FDC ASAQ fixed-dose combination 
artesunate–amodiaquine
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Understanding of FDC ASAQ intake in the exit interview 
group
Of the 120 patients in the exit interview group, 28 
(23.3 %) had come without and 92 (76.7 %) with a care-
taker to the OPDs. Of this group, 87.5 % (105/120) knew 
that they had malaria or could name the correct signs/
symptoms of malaria. Eighty-nine percent (107/120) were 
able to identify the FDC ASAQ tablets (in combination 
with paracetamol) as anti-malarials among all the tablets 
given (Table 4). Eighty-nine percent (107/120) were able 
to correctly repeat the full FDC ASAQ intake instruc-
tions given to them at the OPDs. Of the 10.8 % (13/120) 
who were not able to correctly repeat these instructions, 
the two most common errors were to take the second 
dose in the evening of the first day of treatment intake 
(46.2 %, 6/13) or to split the dose in half and take the first 
half in the morning and the second half in the evening 
(30.8  %, 4/31). Ninety-five percent (114/120) said they 
would continue with the FDC ASAQ intake even if they/
the patient felt better during the treatment period.
According to patients/caretakers, 72.5  % (87/120) of 
the health staff in the OPDs had asked them if they had 
understood the FDC ASAQ intake instructions. Only 
32.5  % (39/120) were asked to repeat these instructions 
and 35.8 % (43/120) were given additional information by 
health staff related to FDC ASAQ. In most cases (72.1 %, 
31/43) this advice was to take sugar water or eat before 
the FDC ASAQ intake.
Discussion
The results of this study show that good adherence to 
the correct intake of FDC ASAQ is possible even in 
this remote, conflict-affected region. The high reported 
rate (75  %) of probable adherence in this rural area is 
encouraging and could help prolong the effectiveness of 
first-line malaria treatment regimens. However, there 
Table 2 General characteristics of adherence study population (patients and caretakers)
a 7/56, 16/56 or 33/56 patients who came to the OPDs without a caretaker
Patient (n = 148) Caretaker (n = 92)
n % n %
Age classes (years)
 <5 42 28.4 – –
 ≥5 106 71.6 92 100.0
 Mean, median (minimum–maximum) 13.4, 10 (1–60) 34.4, 32 (13–68)
Gender
 Male 62 41.9 26 28.3
 Female 86 58.1 66 71.7
Highest education level
 Illiterate 7a 12.5 21 22.8
 Primary 16a 28.6 23 25.0
 Secondary 33a 58.9 43 46.7
 Higher – – 5 5.5
Household size
 1–4 members 9 6.1
 5–15 members 114 77.0
 >15 members 25 16.9
 Mean household size (members) 10.6
Household owns ≥1 insecticide-treated mosquito net 137 92.6
Numbers of children <5 years per households
 0 children 14 9.5
 1 child 28 18.9
 2–4 children 91 61.5
 5–9 children 15 10.1
Mean number of children <5 years per household 2.4
Main 3 professions of heads of households
 Subsistence farmer 58 39.2
 Civil servant 15 10.1
 Teacher 13 8.8
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was a (non-significant) finding that patients younger 
than 5  years were less likely to be completely adherent 
(62 %), which is concerning since children are more likely 
to develop severe disease, increasing the risk of drug 
resistance.
When assessing the main reason for correct FDC 
ASAQ intake, almost all patients claimed they under-
stood the instructions given to them at the OPDs. When 
assessing the exit interview group, an equally positive 
statement can be made for the quality of FDC ASAQ pre-
scriptions and the instructions given at the OPDs: almost 
all patients were able to identify FDC ASAQ as the anti-
malarial treatment amongst other concomitant treat-
ments and could correctly repeat the instructions given 
to them in the OPDs. This shows much better quality of 
anti-malarial prescriptions than in a similar study con-
ducted in The Gambia where only a third of caretakers 
were able to name the disease for which they had visited 
the health facility [30, 31].
ACT should ideally be prescribed in combination with 
paracetamol. Very positively, almost 96 % of patients had 
received a prescription for paracetamol. According to the 
home interviews, adherence to paracetamol was high, 
with more than 90 % of patients with a paracetamol pre-
scription taking it with the FDC ASAQ.
Only 11.5  % of patients were certainly non-adherent 
with another 13.5  % meeting the criteria for probable 
non-adherence. Of the patients that were non-adherent 
(certain and probable), in two-thirds this was related to 
incomplete intake and in one-third to incorrect intake. 
The main reasons patients gave for incomplete intake 
was that the treatment made them feel sick or there was 
neither food nor sugar water at home. Two-thirds of the 
patients with incomplete intake did not take their third 
and last dose of FDC ASAQ. This result might be linked 
to the finding in the exit interviews that only a third of 
patients or caretakers were given any additional informa-
tion related to FDC ASAQ. Of those who received addi-
tional information, none mentioned being told that the 
treatment may cause sickness and fatigue. The health staff 
placed emphasis on taking the treatment together with 
food or sugar water, which might have led to patients 
deciding to miss a dose rather than take it on an empty 
stomach. Around two-thirds of patients who took the 
drug incorrectly did so because they vomited immedi-
ately after intake. The remaining few patients with incor-
rect intake mostly took the second dose in the evening of 
the first day of treatment intake. These results matched 
the results of the exit interview group: only 10  % could 
not correctly repeat the instructions for FDC ASAQ 
intake, the most common error was to take the second 
dose in the evening of the first day.
None of the risk factors such as age, education level, 
and knowledge of malaria were associated with an 
increased risk for non-adherence. Nevertheless the 
study population seems to have a relatively high level of 
understanding of the disease, shown previously to be sig-
nificantly linked to good adherence [32]. This could be 
linked to the slightly higher level of education in study 
population compared to the national average [33]. Two-
thirds of adherence interviewees said they knew the 
cause of malaria and almost 80  % knew that sleeping 
under an insecticide-treated mosquito net is a means of 
prevention. In the exit interview group, 80 % of patients 
Table 3 Reasons for  incomplete, incorrect or correct FDC 
ASAQ intake
FDC ASAQ fixed-dose combination artesunate–amodiaquine, OPD outpatient 
department
a Other reasons were: (i) caretaker did everything to ensure that the child gets 
better; and (ii) the MSF health educator told patient the correct intake of the 
treatment
b Other reasons were: (i) health staff at OPD were very busy; (ii) the teacher and 
not a caretaker brought the child to the OPD; and (iii) caretaker reported that 
health staff did not want to give first dose at the OPD, as the patient’s sister was 
known to have reacted previously adversely
n = 149 %
Reasons given for incomplete intake (n = 25)
 Sickness after FDC ASAQ intake 7 28.0
 No food/sugar available in the household for FDC 
ASAQ intake
5 20.0
 Forgot to give/take FDC ASAQ 3 12.0
 Reported that instructions at OPD were not under-
stood
3 12.0
 Patient felt better, no reason to continue with FDC 
ASAQ intake
3 12.0
 Reported vomiting after FDC ASAQ intake 3 12.0
 Could not find blister to finalize the FDC ASAQ intake 1 4.0
Reasons given for incorrect intake (n = 12)
 Reported vomiting after FDC ASAQ intake 8 66.7
 Sickness after FDC ASAQ intake 2 16.7
 Thought patient would get better faster 1 8.3
 Reported that instructions at OPD were not under-
stood
1 8.3
Reasons given for correct intake—first dose given at OPD (n = 74)
 Reported that correct intake instructions were given 
at OPD
65 87.8
 Knew how to take/give FDC ASAQ from previous 
treatment
6 8.1
 Other reasonsa 2 2.7
 No reasons given 1 1.4
Reasons given for correct intake—first dose taken at home (n = 37)
 Patient had not eaten prior to OPD visit 18 48.6
 OPD told patient/caretaker to take/give first dose at 
home
7 18.9
 No reasons given 9 24.4
 Other reasonsb 3 8.1
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or caretakers could name malaria or knew the signs and 
symptoms.
Two different methods, considered to be complemen-
tary, were used to measure adherence in patients: the pill 
count and a systematic questionnaire. Biological assays 
may offer more precise adherence measurements [34–
36]. They are, however, dependent on the availability of 
laboratory testing and, therefore, not practical in many 
resource-limited and unstable settings. Both the assess-
ment methods we used have their limitations: the pill 
count is a more objective measurement; if the interview-
ers observe remaining tablets, they can be absolutely cer-
tain that the patient is non-adherent. The questionnaire 
gives more complete information, such as on timing of 
doses, but is subjective and not verifiable. By classifying 
patients as either certainly or probably non-adherent, the 
Table 4 General characteristics and understanding of anti-malarial treatment intake in the exit interview study popula-
tion
FDC ASAQ fixed-dose combination artesunate–amodiaquine, OPD outpatient department
a Number of patients who came to the OPDs without a caretaker
b 1 missing value
Patients (n = 120) [n (%)] Caretakers (n = 92) [n (%)]
Age (years)
 <5 43 (35.8) –
 ≥5 77 (64.2) 92 (100.0)
 Mean, median (minimum–maximum) (years) 10, 5 (0–60) 28, 27 (10–68)
Gender
 Male 64 (53.3) 9 (9.8)
 Female 56 (46.7) 83 (90.2)
Highest education level
 Illiterate 3/28a (10.7) 17/91b (18.7)
 Primary level 12/28a (42.9) 37/91b (40.6)
 Secondary level 12/28a (42.9) 35/91b (38.5)
 Higher level 1/28a (3.5) 2/91b (2.2)
n [%]
Perception of disease (n = 120)
 Able to name disease as malaria 33 27.5
 Able to name signs/symptoms of malaria 72 60.0
 Disease and its signs/symptoms unknown or other symptoms mentioned 15 12.5
Perception of anti-malarial treatment (n = 120)
 Able to show FDC ASAQ as only malaria treatment 97 80.8
 Able to show FDC ASAQ together with paracetamol 10 8.3
 Shows only paracetamol 2 1.7
 Unable to distinguish any given treatment 11 9.2
n/N [%]
Patient or caretaker of patient
 Was able to correctly repeat the instructions for FDC ASAQ intake 107/120 89.2
 Errors made while repeating the instructions for FDC ASAQ intake 13/120 10.8
  Second dose will be wrongly taken at first intake day in the evening 6/13 46.2
  Split dose in half and take first half in the morning and second half in the evening 4/13 30.8
  Unable to repeat instructions 2/13 15.4
  Will start with FDC ASAQ the next day (first dose was not given at OPD) 1/13 7.7
Will continue with treatment although patient feels better the next day 114/120 95.0
OPD role
 Was asked in the OPD if she/he had understood instructions 87/120 72.5
 Was asked to repeat instructions 39/120 32.5
 Was given additional information related to FDC ASAQ 43/120 35.8
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study took the limitations of both assessment methods 
into account. To reduce error, patients were asked non-
judgmentally about medication-taking behaviours and 
the delay between treatment and questionnaire adminis-
tration was minimized—none of the interviews were car-
ried out later than 2 days after completing treatment [18]. 
Exit interviews were added to the study design to gain 
information on treatment attitudes and to assess pre-
scription quality. Use of the three complementary meth-
ods strengthened the findings of the study.
One of the most difficult things to avoid in adherence 
studies is influencing health staff such that they change 
prescribing habits. It is also important not to alert 
patients that there might be a later check-up regarding 
the treatment in order to avoid good-will bias [12, 17, 37]. 
The following measures were taken to limit these sources 
of bias: the screening questionnaire was carried out for 
malaria and non-malaria patients attending the OPDs 
to avoid raising any suspicion among the health staff, 
patients or their caretakers. Informed written consent 
was sought only from those patients interviewed at home. 
The true nature of the study was not revealed to the OPD 
health staff at the time of the study. Exit interviews took 
place only after all the screening questionnaires had been 
completed so as not to influence anybody involved in the 
study.
Initially the authors’ wanted to include the hospital 
centre in the village of Matili, located roughly an hour’s 
car journey from Shabunda town, as a study site. How-
ever, due to the deteriorating security situation in the 
region, only Shabunda town health facilities were able to 
be included. As very remote areas are usually linked to 
lower adherence, lower adherence levels might have been 
found if the most remote areas of Shabunda Health Zone 
had been included.
Although more patients were eligible to participate 
in the study, the deteriorating security situation in the 
region meant that data collection needed to be com-
pleted as quickly as possible. Participant recruitment was 
therefore stopped once the calculated sample size had 
been reached.
In 2005, the first systematic review on malaria adher-
ence concluded that there was insufficient information 
on this subject and research would benefit from of stand-
ardization of methodologies [38]. In 2014, the second 
systematic review on adherence to ACT treatment was 
published but only 37 studies were eligible for inclusion 
[17]. The lack of uniform methodology and definitions 
for adherence makes comparison between studies diffi-
cult. Only a few of the eligible 37 studies used detailed 
definitions of adherence that included doses, duration, 
and frequency and many revealed the purpose of the 
study and alerted the study population to home visits to 
assess treatment intake.
In the seven studies carried out on adherence to the 
ACT combination ASAQ in Africa between 2008 and 
2012, adherence varied between 48 and 97  %. In three 
studies in which adherence was >90 % the purpose of the 
study was known both by health staff and the study pop-
ulation [39–41]. In two studies with adherences of 48 and 
77 %, respectively, health staff and the study population 
were not aware that adherence would be assessed [28, 
42]. In the only two studies that were carried out with 
FDC ASAQ, adherence was as high as 83 and 90 %. How-
ever, both studies were designed as effectiveness stud-
ies with adherence as a secondary objective and study 
patients were aware that adherence would be assessed 
[23, 24].
The adherence result of 75  % in this study is higher 
than in studies with a related design (conducted in rou-
tine health service delivery with patients/caregivers not 
informed about the aim in advance), methodology (self-
reports from patients/caregivers in combination with pill 
counts), similar study areas (remote rural areas), and pre-
conditions (anti-malarial treatment already implemented 
for some time). In Ethiopia, adherence was 39 %, in Zam-
bia 40 %, in Sierra Leone 48 %, in South Sudan 53 %, in 
the Central African Republic 61 % and in Kenya 64 % [12, 
25–27, 43, 44].
In the exit interview group, almost half the patients or 
their caretakers claimed not to have taken the first treat-
ment dose under supervision in the OPDs. According 
to adherence interviews, the main reason was that the 
patients had not eaten prior to the OPD visit and there-
fore were told to take the first dose at home together with 
food. Given the high overall adherence in the study, the 
intake of the first dose under supervision does not seem 
to have a big influence on adherence and contradicts the 
results of previous studies where supervised intake of the 
first anti-malarial treatment was directly correlated with 
higher adherence [38, 42, 44].
Access to prompt and effective treatment is a corner-
stone of the current malaria control strategy. A delay in 
starting appropriate treatment is a major contributor to 
malaria mortality. Many patients and especially children 
with suspected malaria, where medical services are not 
easily accessible, start treatment too late or do not receive 
it at all and die at home. Therefore, since 2004, WHO 
has recommended home- or community-based manage-
ment of malaria by trained community health workers as 
one of the strategies for improving access to prompt and 
effective malaria case management [45]. However, crucial 
to the sustainable success of community-based malaria 
management is strengthening health system capacities 
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to support supply, for training and close quality supervi-
sion, and foremost for appropriate treatment of referred 
cases [46, 47]. In a study carried out in Uganda, only one 
in five community health workers performed optimally 
[48]. If adequate resources for community-based malaria 
management are not given and close monitoring of 
activities cannot be guaranteed, it might be necessary to 
first increase the capacity for correct malaria case iden-
tification and management at the peripheral health cen-
tre level. The results of the study provide evidence that 
patient adherence to the correct intake of ACT and high-
quality prescribing at health centre level is possible in this 
setting, despite being remote and largely unstable. High 
levels of adherence to ACT prescribed in health facili-
ties might be a first step to the successful introduction 
of home- or community based management of malaria. 
High levels of resistance to older anti-malarials mean that 
ACT should remain the first-line treatment for malaria. 
The effectiveness of ACT depends on its efficacy and on 
adherence to treatment. Assessments of ACT adherence 
at the household and exit interviews at the health facility 
level should be used to inform operational programming 
in areas of high malaria-burden to maximise the thera-
peutic value of the treatment. Moreover, further ways to 
prevent and diagnose malaria need to be explored.
Conclusions
To the authors’ knowledge, this is the first study to assess 
adherence to an FDC of ACT under real treatment con-
ditions in a context of high instability. High quality pre-
scribing of anti-malarials at health centre level and 
patient adherence to the correct intake of ACT were pos-
sible in this setting. Adherence to treatment regimens 
requires careful and constant monitoring, which might 
be better guaranteed at health centre rather than com-
munity level. It could, nevertheless, be a precondition 
to the successful introduction of home- or community 
based management of malaria.
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